245 related articles for article (PubMed ID: 27149663)
1. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
Mailankody S; Prasad V
JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
[No Abstract] [Full Text] [Related]
2. Linking performance with payment: implementing the Physician Value-Based Payment Modifier.
VanLare JM; Blum JD; Conway PH
JAMA; 2012 Nov; 308(20):2089-90. PubMed ID: 23198298
[No Abstract] [Full Text] [Related]
3. Specialty pharmacy management will become more intense.
Collins S
Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783
[No Abstract] [Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. The pills that ate your profits.
Meyer H
Hosp Health Netw; 1998 Feb; 72(3):18-22. PubMed ID: 9483145
[TBL] [Abstract][Full Text] [Related]
6. Implications of new insurance coverage for access to care, cost-sharing, and reimbursement.
James AE; Gellad WF; Primack BA
JAMA; 2014 Jan; 311(3):241-2. PubMed ID: 24337312
[No Abstract] [Full Text] [Related]
7. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
Cohen J; Malins A; Shahpurwala Z
Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
[TBL] [Abstract][Full Text] [Related]
8. Killing U.S. Slowly: Curing the Epidemic Rise of Cancer Drug Prices.
White EK
Food Drug Law J; 2017; 72(1):189-224. PubMed ID: 29140658
[TBL] [Abstract][Full Text] [Related]
9. Economic incentives and barriers to quality care.
Coutts LR
Nephrol News Issues; 2007 May; 21(6):5. PubMed ID: 17518116
[No Abstract] [Full Text] [Related]
10. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
Hwang TJ; LaMattina JL
JAMA Oncol; 2016 Sep; 2(9):1125-6. PubMed ID: 27388928
[No Abstract] [Full Text] [Related]
11. Cost-Sharing for Part B Chemotherapy Drugs in Medicare Advantage Plans: an Administrative Data Analysis.
Keohane LM; Finch CJ
J Gen Intern Med; 2019 Jul; 34(7):1119-1120. PubMed ID: 30805824
[No Abstract] [Full Text] [Related]
12. Area variation in Medicare physician spending.
Mitchell JB
Health Aff (Millwood); 1992; 11(1):224-34. PubMed ID: 1577378
[No Abstract] [Full Text] [Related]
13. Does CMS' Part B drug proposal usurp clinical judgment?
Dickson V
Mod Healthc; 2016 Mar; 46(11):8-9. PubMed ID: 27079029
[No Abstract] [Full Text] [Related]
14. Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D.
Dusetzina SB
N Engl J Med; 2022 Jun; 386(23):2164-2167. PubMed ID: 35507526
[No Abstract] [Full Text] [Related]
15. Rising Cost of Anticancer Medications in the United States.
Jackson K; Nahata MC
Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
[TBL] [Abstract][Full Text] [Related]
16. Aetna takes exit cue. Low reimbursement rates cause nine-state pullback.
Rauber C
Mod Healthc; 1998 Sep; 28(36):12. PubMed ID: 10185550
[No Abstract] [Full Text] [Related]
17. Medicare cost containment strategy targets several oncology drugs.
Twombly R
J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
[No Abstract] [Full Text] [Related]
18. Medicare Part D update--lessons learned and unfinished business.
Neuman P; Cubanski J
N Engl J Med; 2009 Jul; 361(4):406-14. PubMed ID: 19625722
[No Abstract] [Full Text] [Related]
19. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
Gordan L; Grogg A; Blazer M; Fortner B
J Oncol Pract; 2017 Feb; 13(2):e139-e151. PubMed ID: 28029298
[TBL] [Abstract][Full Text] [Related]
20. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
